subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: * dyspnea at rest * respiratory rate \> 30 breaths per minute * spo2 ≤ 93% on room air * heart rate ≥ 125 beats per minute * respiratory distress or respiratory failure. * evidence of critical illness 1. female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. 2. hospitalization or need for hospitalization for any cause 3. treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. 4. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. 5. subjects with the following risk factors: * compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia * known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) * chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen * chronic asthma requiring the use of oral steroids or hospitalization in the last six months * renal failure or renal insufficiency requiring dialysis * congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: * dyspnea at rest * respiratory rate \> 30 breaths per minute * spo2 ≤ 93% on room air * heart rate ≥ 125 beats per minute * respiratory distress or respiratory failure. * evidence of critical illness 1. female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. 2. hospitalization or need for hospitalization for any cause 3. treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. 4. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. 5. subjects with the following risk factors: * compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia * known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) * chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen * chronic asthma requiring the use of oral steroids or hospitalization in the last six months * renal failure or renal insufficiency requiring dialysis * congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: dyspnea at rest respiratory rate > 30 breaths per minute spo2 ≤ 93% on room air heart rate ≥ 125 beats per minute respiratory distress or respiratory failure. evidence of critical illness female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. hospitalization or need for hospitalization for any cause treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. subjects with the following risk factors: compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen chronic asthma requiring the use of oral steroids or hospitalization in the last six months renal failure or renal insufficiency requiring dialysis congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: dyspnea at rest respiratory rate > 30 breaths per minute spo2 ≤ 93% on room air heart rate ≥ 125 beats per minute respiratory distress or respiratory failure. evidence of critical illness female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. hospitalization or need for hospitalization for any cause treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. subjects with the following risk factors: compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen chronic asthma requiring the use of oral steroids or hospitalization in the last six months renal failure or renal insufficiency requiring dialysis congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: - dyspnea at rest - respiratory rate > 30 breaths per minute - spo2 ≤ 93% on room air - heart rate ≥ 125 beats per minute - respiratory distress or respiratory failure. - evidence of critical illness 1. female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. 2. hospitalization or need for hospitalization for any cause 3. treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. 4. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. 5. subjects with the following risk factors: - compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia - known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) - chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen - chronic asthma requiring the use of oral steroids or hospitalization in the last six months - renal failure or renal insufficiency requiring dialysis - congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

subjects who meet any of the criteria of severe or higher covid-19 will be excluded from the study: - dyspnea at rest - respiratory rate > 30 breaths per minute - spo2 ≤ 93% on room air - heart rate ≥ 125 beats per minute - respiratory distress or respiratory failure. - evidence of critical illness 1. female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. 2. hospitalization or need for hospitalization for any cause 3. treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. 4. use of other drugs that, in the opinion of the investigator, could complicate analysis of sab-185. 5. subjects with the following risk factors: - compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia - known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) - chronic respiratory disease including copd, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen - chronic asthma requiring the use of oral steroids or hospitalization in the last six months - renal failure or renal insufficiency requiring dialysis - congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. receipt of pooled immunoglobulin or plasma in past 30 days 7. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of sab-185 8. known iga deficiency or previous allergic reaction to intravenous immunoglobin (ivig)/subcutaneous immunoglobin (scig) 9. positive for hepatitis b virus surface antigen, hepatitis c virus antibody, or hiv antibody by medical history 10. history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).